Udayavni Special

COVID-19: HCQ consignment from India reaches US

PTI, Apr 12, 2020, 3:27 PM IST

Washington: A consignment of hydroxychloroquine from India has reached the US, the global COVID-19 hotspot, days after New Delhi lifted a ban on the export of the anti-malarial drug to America and some other countries on humanitarian grounds to help them combat the coronavirus pandemic.

More than 1.7 million people have tested positive and 108,867 people have died from the novel coronavirus globally. The United States has emerged as the global hotspot with 20,000 deaths and nearly 530,000 cases, According to Johns Hopkins University data.

America has replaced Italy as the country with the highest number of COVID-19 deaths at 20,597, the data shows.

Earlier this week, India at the request of President Donald Trump cleared the export of 35.82 lakh tablets of hydroxychloroquine to the US along with nine metric tons of active pharmaceutical ingredient or API required in the manufacturing of the drug.

“Supporting our partners in the fight against COVID-19. Consignment of hydroxychloroquine from India arrived at Newark airport today (Saturday),” India’s Ambassador to the US Taranjit Singh Sandhu tweeted.

Trump, during a phone call last week, asked Prime Minister Narendra Modi to lift the hold on American order of the anti-malarial drug, of which India is the major producer. India, which manufactures 70 per cent of the world’s supply of hydroxychloroquine, lifted the ban on April 7.

Hydroxychloroquine has been identified by the US Food and Drug Administration as a possible treatment for the COVID-19 and it is being tested on more than 1,500 coronavirus patients in New York.

Anticipating that it will work, given the initial positive results, Trump has bought more than 29 million doses of hydroxychloroquine for the potential treatment of COVID-19 patients.

The arrival of consignment was welcomed by Americans.

“US will never forget this great humanitarian gesture by India. Under President Trump and Prime Minister Narendra Modi, the two largest democracies of the world have come together than ever in the past,” said New York-based Al Mason, a real estate consultant and a Trump supporter.

“A wonderful gesture by India to its friends in need,” tweeted Dr Sampat Shivangi.

Describing this as a “wonderful gesture,” Steve Filipovic, who works in the construction industry, thanked the Indian Ambassador.

Meanwhile, according to a new French study, of the 1,061 hospitalised COVID-19 patients showed a 91.7 per cent cure (viral shedding) within 10 days of hydroxychloroquine treatment along with antibiotic. It also reported a 96 per cent cure rate after 15 days.

Early this week, the National Institute of Health reported that a clinical trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalised with the coronavirus disease had begun, with the first participants now enrolled in Tennessee.

Hydroxychloroquine is used to treat malaria and rheumatoid conditions such as arthritis. In various studies, the drug has demonstrated antiviral activity, an ability to modify the activity of the immune system, and has an established safety profile at appropriate doses, leading to the hypothesis that it may also be useful in the treatment of COVID-19, the NIH said.

The drug is not without risks as even short-term use can cause cardiac arythmias, seizures, dermatological reactions, and hypoglycemia, it added.

“Many US hospitals are currently using hydroxychloroquine as first-line therapy for hospitalized patients with COVID-19 despite extremely limited clinical data supporting its effectiveness,” said Wesley Self, emergency medicine physician at Vanderbilt University Medical Center and PETAL Clinical Trials Network investigator leading the ORCHID trial.

“Thus, data on hydroxychloroquine for the treatment of COVID-19 are urgently needed to inform clinical practice,” he added.

According to NIH, participants will be randomly assigned to receive hydroxychloroquine 400 mg twice daily for two doses (day one), then 200 mg twice daily for the subsequent eight doses (days two to five) or a placebo twice daily for five days.

COVID-19 cases were first identified in December 2019 in Wuhan, the capital of Hubei Province in China.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Navy finds some debris of crashed MiG-29K in Arabian sea

Serum Institute rejects charges levelled by vaccine trial participant, threatens to seek damages

K’taka COVID-19 update: 1291 new cases, 1530 recoveries, 15 deaths on Nov 28

India ‘pharmacy of world,’ focusing on deeper ties in S&T: Swedish amb

PM hailing farm laws shows govt ‘drunk with power’, ‘rigid’ in face of protests: Cong

UP registers first case under anti-conversion law in Bareilly

Modi’s Hyd visit: A testimony of Telangana achievement, KCR should have been invited, says KTR


Meet the man with the largest collections of Newspapers | Umesh Rao Ekkar Mangalore

Mangalore: Woman rescues a cat from 30 feet deep well | Ranjini Shetty | Udayavani

CM and central leadership will take final call on Cabinet expansion: Ashwath Narayan

Assorted flowers, fruits, and vegetables are grown in the terrace garden

Celebrating 25 Years of Laveena Masala | Since 1996 | Udayavani

Latest Additions

Navy finds some debris of crashed MiG-29K in Arabian sea

Serum Institute rejects charges levelled by vaccine trial participant, threatens to seek damages

Will Hold Punjab CM Responsible if Farmers’ Gatherings Aggravate Covid in Haryana, Says Khattar

High Octane Campaign for Hyderabad Polls Ends; 67 Lakh Voters to Decide Fate of 1,222 Candidates on Dec 1

K’taka COVID-19 update: 1291 new cases, 1530 recoveries, 15 deaths on Nov 28

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.